Diary - News
All news Transgene and AstraZeneca enter into a collaboration and exclusive license option agreement
• 5 novel oncolytic immunotherapies will be developed based on Transgene’s new Invir.IOTM platform
• Transgene to receive $10 million upon signing and is eligible to receive further development milestone payments and royalties
Strasbourg (France), May 2, 7:30 a.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies against cancers and infectious diseases announces the signing of a collaborative research, option and exclusive license agreement with AstraZeneca to co-develop five armed oncolytic vaccinia virus candidates. Innovative oncolytic viruses resulting from this collaboration will use Transgene’s proprietary next generation viral platform Invir.IOTM.
